Home > Healthcare > Pharmaceuticals > Finished Drug Form > Acetaminophen Market

Acetaminophen Market Trends

  • Report ID: GMI5935
  • Published Date: Jun 2023
  • Report Format: PDF

Acetaminophen Market Trends

Rising number of chronic diseases and pain management including for degenerative disc disease treatment conditions is a major factor driving the market expansion. For instance, as per the World Health Organization (WHO), approximately 1.71 billion people have musculoskeletal conditions worldwide. Paracetamol is widely recommended as the first choice for age-related musculoskeletal conditions that cause chronic pain and disability. Also, paracetamol has been assessed in different conditions and demonstrated therapeutic efficacy for both acute and chronic pain. It is active as a single agent and is synergistic with NSAIDs and opioids, improving their efficacy and safety.
 

Further, fast dissolving formulations of paracetamol provide superior and more extended pain relief. The drug has been recommended as a first or second-line drug for acute pain and chronic pain, especially for patients with limited therapeutic options and for the elderly. Thus, growing cases of chronic diseases leading to pain will spur the market outlook.
 

Acetaminophen Market Restraint

A key restraint is that regular use of acetaminophen medications can cause high blood pressure. Long-term use of paracetamol is associated with a high risk of heart disease and strokes in consumers with high blood pressure. As per the latest clinical study conducted by researchers at the University of Edinburgh in 2022, paracetamol when given in patients with high blood pressure, saw a significant increase in blood pressure compared with those taking the placebo. Additionally, paracetamol toxicity due to either accidental or intentional overdose is an ongoing global problem that continues to result in cases of hepatotoxicity and acute liver toxicity.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Acetaminophen market size was USD 9.8 billion in 2022 and will record over 4.8% CAGR between 2023 to 2032.

The parenteral route of administration segment will reach around USD 1.3 billion by the end of 2032 as it offers direct and rapid delivery of the drug into the bloodstream.

North America holds the largest regional share in acetaminophen market due to the presence of key players, high incidence of fever, headaches, migraine, and a well-structured healthcare system.

BRISTOL-MYERS SQUIBB, Bayer AG, Sun Pharmaceutical Industries Limited, Glaxo SmithKline Pharmaceuticals Ltd, Alkem Laboratories Ltd, Abbott, B.BRAUN MELSUNGEN, Novartis AG, IOL Chemicals and Pharmaceuticals, Lupin Ltd, and Teva Pharmaceuticals USA, Inc.

Acetaminophen Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 19
  • Tables & Figures: 268
  • Countries covered: 20
  • Pages: 180
 Download Free Sample